Atara posts Q4 loss $0.56/sh; tab-cel BLA submission on track for Q2 2024

Atara Biotherapeutics, Inc.

Q4 net loss $60.5M ($0.56/diluted share); FY 2023 net loss $276.1M ($2.61/diluted share).
Cash, cash equivalents and short-term investments $51.7M at Dec 31, 2023; pro-forma ~$104M after Q1 2024 proceeds.
Tab-cel BLA submission on track for Q2 2024; $20M regulatory milestone expected in April 2024.
ATA3219 lupus nephritis Phase 1 to start H2 2024, initial data H1 2025; NHL study enrolling with data Q4 2024.
Two workforce reductions: ~30% in Nov 2023 and further ~25% in Jan 2024; headcount now ~170.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Atara Biotherapeutics, Inc. reported the fourth quarter and full year 2023 results: net income net losses of $60.5 million, or $0.56 per share, and $276.1 million, or $2.61 per share, for the fourth quarter and fisc, EPS $0.56 per share for the fourth quarter and $2.61 per share for the fiscal year 2023.

Period: the fourth quarter and full year 2023
Net income: net losses of $60.5 million, or $0.56 per share, and $276.1 million, or $2.61 per share, for the fourth quarter and fisc
EPS: $0.56 per share for the fourth quarter and $2.61 per share for the fiscal year 2023
Result: reported results

Exact text from the filing

Fourth Quarter and Full Year 2023 Financial Results • Cash, cash equivalents and short-term investments as of December 31, 2023 totaled $51.7 million, as compared to $102.4 million as of September 30, 2023 and $242.8 million as of December 31, 2022 • Net cash used in operating activities was $50.4 million and $193.0 million for the fourth quarter and fiscal year 2023, as compared to $56.9 million and $270.4 million in the same periods in 2022 • Atara reported net losses of $60.5 million, or $0.56 per share, and $276.1 million, or $2.61 per share, for the fourth quarter and fiscal year 2023, respectively, as compared to $74.6 million, or $0.72 per share, and $228.3 million, or $2.24 per share, for the same periods in 2022

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-037643

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.